A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma
A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma
About this item
Full title
Author / Creator
Publisher
Japan: Springer Japan
Journal title
Language
English
Formats
Publication information
Publisher
Japan: Springer Japan
Subjects
More information
Scope and Contents
Contents
Background
This study was conducted to evaluate the efficacy of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib with pegylated-IFNα (PEG-IFNα) in patients with advanced renal cell carcinoma.
Methods
Progression-free survival (PFS) rate at 6 months >50% was considered promising for further evaluation. Patients with...
Alternative Titles
Full title
A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmed_primary_21431345
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_21431345
Other Identifiers
ISSN
1341-9625
E-ISSN
1437-7772
DOI
10.1007/s10147-011-0212-8
